Boulder-based oncology company Enliven Therapeutics raises $55M Series A
BOULDER — Enliven Therapeutics Inc., a Boulder-based cancer-drug developer, is exiting from stealth operations by announcing that it raised $55 million in its first funding round.
The Series A round includes an unspecified investment from the venture-capital arm of Swiss health-care company Roche Holding AG, the company said in a statement. Life science-focused venture-capital firms Orbimed Advisors LLC and 5AM Venture Management LLC also contributed to the round.
However, the company has not specified what exact types of cancers it’s seeking to address outside of targeting cancers with “suboptimal drugs,” or published its pipeline of drug…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Boulder-based publishing technology company Sovrn Holdings Inc. has named Will Duckworth its chief technology officer.
-
A Boulder fiber infrastructure company and broadband internet provider said it has raised $80 million…
-
Knowledge Factor Inc., a software-as-a-service company that provides cognitive science-based assessment, training and data analytics…
-
Playa Bowls, a national restaurant chain specializing in fruit bowls and smoothies, will soon open…
